Seek Returns logo

ABBV vs. TMUS: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ABBV and TMUS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolABBVTMUS
Company NameAbbVie Inc.T-Mobile US, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareCommunication Services
GICS IndustryBiotechnologyWireless Telecommunication Services
Market Capitalization366.65 billion USD283.31 billion USD
ExchangeNYSENasdaqGS
Listing DateJanuary 2, 2013April 19, 2007
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of ABBV and TMUS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. TMUS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolABBVTMUS
5-Day Price Return0.66%-2.51%
13-Week Price Return13.70%4.53%
26-Week Price Return5.17%-4.41%
52-Week Price Return5.69%28.15%
Month-to-Date Return9.80%5.59%
Year-to-Date Return16.80%14.05%
10-Day Avg. Volume4.52M3.71M
3-Month Avg. Volume6.27M4.42M
3-Month Volatility19.40%23.82%
Beta0.490.61

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

ABBV’s Return on Equity of 95.59% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

TMUS

19.69%

Wireless Telecommunication Services Industry

Max
27.67%
Q3
18.94%
Median
13.35%
Q1
6.38%
Min
-8.07%

In the upper quartile for the Wireless Telecommunication Services industry, TMUS’s Return on Equity of 19.69% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ABBV vs. TMUS: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

TMUS

14.53%

Wireless Telecommunication Services Industry

Max
17.18%
Q3
13.67%
Median
9.33%
Q1
4.43%
Min
-5.10%

A Net Profit Margin of 14.53% places TMUS in the upper quartile for the Wireless Telecommunication Services industry, signifying strong profitability and more effective cost management than most of its peers.

ABBV vs. TMUS: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

TMUS

23.08%

Wireless Telecommunication Services Industry

Max
29.85%
Q3
23.51%
Median
20.46%
Q1
16.06%
Min
9.07%

TMUS’s Operating Profit Margin of 23.08% is around the midpoint for the Wireless Telecommunication Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

ABBV vs. TMUS: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Profitability at a Glance

SymbolABBVTMUS
Return on Equity (TTM)95.59%19.69%
Return on Assets (TTM)2.73%5.78%
Net Profit Margin (TTM)6.45%14.53%
Operating Profit Margin (TTM)18.80%23.08%
Gross Profit Margin (TTM)70.93%63.61%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

ABBV’s Current Ratio of 0.74 is notably low, falling beneath the typical range for the Biotechnology industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.

TMUS

1.21

Wireless Telecommunication Services Industry

Max
1.26
Q3
1.00
Median
0.71
Q1
0.60
Min
0.36

TMUS’s Current Ratio of 1.21 is in the upper quartile for the Wireless Telecommunication Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

ABBV vs. TMUS: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

TMUS

1.45

Wireless Telecommunication Services Industry

Max
2.92
Q3
2.15
Median
1.57
Q1
0.91
Min
0.44

TMUS’s Debt-to-Equity Ratio of 1.45 is typical for the Wireless Telecommunication Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ABBV vs. TMUS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

TMUS

5.31

Wireless Telecommunication Services Industry

Max
12.67
Q3
6.16
Median
3.95
Q1
1.81
Min
-1.20

TMUS’s Interest Coverage Ratio of 5.31 is positioned comfortably within the norm for the Wireless Telecommunication Services industry, indicating a standard and healthy capacity to cover its interest payments.

ABBV vs. TMUS: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Financial Strength at a Glance

SymbolABBVTMUS
Current Ratio (MRQ)0.741.21
Quick Ratio (MRQ)0.481.08
Debt-to-Equity Ratio (MRQ)49.221.45
Interest Coverage Ratio (TTM)2.705.31

Growth

Revenue Growth

ABBV vs. TMUS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. TMUS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

3.11%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ABBV’s Dividend Yield of 3.11% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

TMUS

1.29%

Wireless Telecommunication Services Industry

Max
7.63%
Q3
5.13%
Median
3.22%
Q1
2.33%
Min
0.00%

TMUS’s Dividend Yield of 1.29% is in the lower quartile for the Wireless Telecommunication Services industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

ABBV vs. TMUS: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

TMUS

30.87%

Wireless Telecommunication Services Industry

Max
145.86%
Q3
109.87%
Median
78.85%
Q1
48.65%
Min
0.00%

TMUS’s Dividend Payout Ratio of 30.87% is in the lower quartile for the Wireless Telecommunication Services industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

ABBV vs. TMUS: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Dividend at a Glance

SymbolABBVTMUS
Dividend Yield (TTM)3.11%1.29%
Dividend Payout Ratio (TTM)226.84%30.87%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

96.80

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

At 96.80, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

TMUS

23.93

Wireless Telecommunication Services Industry

Max
34.45
Q3
23.52
Median
16.68
Q1
13.97
Min
7.48

A P/E Ratio of 23.93 places TMUS in the upper quartile for the Wireless Telecommunication Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

ABBV vs. TMUS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

6.24

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

ABBV’s P/S Ratio of 6.24 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

TMUS

3.48

Wireless Telecommunication Services Industry

Max
2.56
Q3
1.94
Median
1.37
Q1
1.22
Min
0.62

With a P/S Ratio of 3.48, TMUS trades at a valuation that eclipses even the highest in the Wireless Telecommunication Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

ABBV vs. TMUS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

TMUS

4.43

Wireless Telecommunication Services Industry

Max
4.87
Q3
2.93
Median
2.02
Q1
1.33
Min
0.40

TMUS’s P/B Ratio of 4.43 is in the upper tier for the Wireless Telecommunication Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ABBV vs. TMUS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Wireless Telecommunication Services industry benchmarks.

Valuation at a Glance

SymbolABBVTMUS
Price-to-Earnings Ratio (TTM)96.8023.93
Price-to-Sales Ratio (TTM)6.243.48
Price-to-Book Ratio (MRQ)261.014.43
Price-to-Free Cash Flow Ratio (TTM)19.9723.69